Afinitor approved for advanced breast cancer

Share this article:
Afinitor Approved for Advanced Breast Cancer
Afinitor Approved for Advanced Breast Cancer

(HealthDay News) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration said Friday.

The newly approved combination is sanctioned for women whose cancer has progressed or returned despite previous use of the drugs letrozole (Femara) or anastrozole (Arimidex), the agency said in a news release.

Afinitor -- already sanctioned for uses which include treating certain forms of advanced renal cell carcinoma -- was clinically evaluated for the new use among 724 people with advanced breast cancer. People who took the combination drug had a 4.6-month improvement in the average time to disease progression or death, compared to those who took a placebo.

The most common side effects among those taking Afinitor were mouth ulcers, infection, rash, fatigue, diarrhea, and loss of appetite.

Afinitor is marketed by Novartis, based in East Hanover, N.J.

More information

The National Cancer Institute has more about breast cancer.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

ASTRO: Sexual function not compromised in prostate cancer combo treatment

ASTRO: Sexual function not compromised in prostate cancer ...

High rates of preserved sexual function seen with combination beam plus brachytherapy for prostate cancer.

Screening elderly women for breast cancer not efficacious

Screening elderly women for breast cancer not efficacious

Mammograms for those aged 69 to 75 could result in over-treatment, researchers caution.

AACR: Targeted drugs and prevention reduce cancer mortality

AACR: Targeted drugs and prevention reduce cancer mortality

About 14.5 million U.S. cancer survivors are alive today, but aging population and increasing obesity threaten progress.